Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

Novo Nordisk has more than enough of its Wegovy weight-loss pills to support an aggressive product launch, CEO Mike Doustdar ...

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...

Wegovy-maker Novo Nordisk's CEO said on Monday a deal with the White House to slash prices on its popular weight‑loss drugs ...

By Jacob Gronholt-Pedersen and Stine Jacobsen COPENHAGEN (Reuters) -Newly-elected chairman of Wegovy-maker Novo Nordisk, Lars ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

Analysts still see 52% upside for Novo Nordisk -- find out whether its blockbuster drugs can spark a major rebound in 2025.

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity ...

Novo Nordisk's CEO Mike Doustdar made a daring $10 billion bid for Metsera to assert dominance in the obesity drugs market, ...

Novo Nordisk A/S is tapping the euro bond market with a multi-tranche sale expected to raise about €3.5 billion ($4.1 billion ...